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Objectives This study reports the results of a series of transapical mitral valve-in-valve implanta-
tions and aims to offer guidance on technical aspects of the procedure.
Background Mitral valve reoperations due to failing bioprostheses are associated with high morbid-
ity and mortality. Transcatheter techniques may evolve as complementary approaches to surgery in
these high-risk patients.
Methods Six patients (age 75  15 years) received transapical implantation of a balloon-expandable
pericardial heart valve into a degenerated bioprosthesis (range 27 to 31 mm) in mitral position at
our institution. All patients were considered high risk for surgical valve replacement (logistic Euro-
SCORE: 33  15%) after evaluation by an interdisciplinary heart team. Procedural and clinical out-
comes were analyzed.
Results Implantation was successful in all patients with reduction of mean transvalvular gradients
from 11.3  5.2 mm Hg to 5.5  3.6 mm Hg (p  0.016) and median regurgitation from grade 3.0
(interquartile range [IQR]: 2.7 to 3.1) to 0 (IQR: 0 to 1.0, p  0.033) with trace paravalvular regurgita-
tion remaining in 2 patients. Apical bleeding occurred in 2 patients requiring rethoracotomy in 1
and resuscitation in a second patient, the latter of whom died on postoperative day 6. In the re-
maining patients, median New York Heart Association functional class improved from 3.0 (IQR: 3.0 to
3.5) to 2.0 (IQR: 1.5 to 2.0, p  0.048) over a median follow-up of 70 (IQR: 25.5 to 358) days.
Conclusions With acceptable results in a high-risk population, transapical mitral valve-in-valve im-
plantation can be considered as a complementary approach to reoperative mitral valve surgery in
select patients. (J Am Coll Cardiol Intv 2012;5:341–9) © 2012 by the American College of
Cardiology Foundation
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342Due to favorable clinical results, bioprostheses have increas-
ingly been chosen over mechanical valves even in younger
patients undergoing surgical valve replacements. As out-
comes improve, a growing need for reoperative valve re-
placements due to xenograft degeneration may be antici-
pated in the future. Mitral valve reoperations can be
associated with a high mortality related to the patients’
clinical condition, significant comorbidities, and the com-
plexity of the procedure itself (1–5).
After proof of principle (6), transcatheter valve-in-valve
therapies have been evolving as promising complementary
approaches to reoperative valve surgery in high-risk surgical
patients, sparing them the need for complex reoperations
associated with the use of extracorporeal circulation. In-
creasing experience with this novel approach has been
collected for the aortic position, and first results seem
appealing in a select patient group (7–11). At the same time,
the technique has been refined and applied in mitral,
tricuspid, and pulmonary positions, but experience is small
when compared with aortic valve-
in-valve implantation and limited to
single case reports or small case
series (10–18). Implantation after
mitral valve repair and annulo-
plasty has also been reported (19).
Different approaches to access the
mitral valve have been advocated,
including transseptal and transa-
trial techniques (11,20). Neverthe-
less, most experience has been
gained using the transapical ac-
cess (11,13). To contribute to
the growing knowledge and un-
derstanding of this novel technique,
we report a series of patients un-
ergoing transapical mitral valve-in-valve implantation at our
nstitution and attempt to offer insights into the technical
hallenges accompanying this procedure.
ethods
Patient population. From December 2009 to July 2011, 6
patients were admitted to our institution with significant
signs of valve dysfunction long term after bioprosthetic
mitral valve replacement (MVR) (Table 1). Indication for
valve replacement was based on current guidelines (21). All
patients presented with severe comorbidities precluding
them from surgical treatment as determined by an interdis-
ciplinary heart team. Pre-operative transesophageal echo-
cardiography was used to determine valve pathology and
inner stent diameter. Coronary angiography was performed
to rule out significant coronary artery disease requiring
Abbreviations
and Acronyms
EOA  effective orifice area
IQR  interquartile range
MR  mitral regurgitation
MVR  mitral valve
replacement
NYHA  New York Heart
Association
TAVI  transcatheter aortic
valve implantation
THV  transcatheter heart
valveintervention.Transapical Valve-in-Valve Implantation
Valve-in-valve implantation was performed in a specially
equipped hybrid suite with a primed heart-lung machine
available in the room in case of hemodynamic compro-
mise. Procedures were performed under general anesthe-
sia, as previously described (10). Briefly, after left lateral
minithoracotomy in the fifth or sixth intercostal space,
ventricular pacemaker leads were placed and purse-string
sutures were applied to the apex. After apical puncture,
soft and subsequent stiff guidewires were inserted
transapically, advanced through the mitral prosthesis, and
placed in the pulmonary vein. In 1 case of severe mitral
stenosis and the inability to cross the calcified bioprosthesis
with the transcatheter heart valve (THV), balloon valvulo-
plasty of the degenerated valve was performed. This step
was not done in the remaining cases. Measurements of the
inner stent diameter of the bioprostheses were obtained by
transesophageal echocardiography, and a 23- or 26-mm
THV was selected for implantation. Compared with
transapical placement of a THV in the aortic position, the
Edwards Sapien valve (Edwards Lifesciences, Irvine, Cali-
fornia) was crimped in a reverse fashion onto the balloon
catheter (Fig. 1). Subsequently, the THV was introduced
through a transapically placed sheath, positioned, and then
deployed into the degenerated mitral bioprosthesis under
fluoroscopic and echocardiographic guidance (Fig. 2). Sim-
ilar to Cheung et al. (14), the THV was placed to slightly
overlap the stent of the degenerated bioprosthesis into the
left atrium for sufficient anchoring. These steps were carried
out under rapid ventricular pacing. Subsequently, valve
performance was assessed by transesophageal echocardiography
and fluoroscopy.
In 2 patients with concomitant intervention of the aortic
valve, a THV was deployed antegrade into the degenerated
bioprosthesis or the calcified aortic annulus (Patients #2 and
#3) (Table 1, Fig. 3), as previously described (10). Implan-
tations in the aortic position were performed before the
mitral valve interventions to allow for better access to the
aortic valve. After small angulation of the sheath and
exchange of the introducer device, mitral valve-in-valve
implantation was performed using the same access route, as
described in the previous text.
Echocardiographic assessment and clinical follow-up.
Transthoracic echocardiography was performed at baseline,
before discharge, and at 30 days according to recent recom-
mendations (22). The effective orifice area (EOA) was
assessed using the continuity equation approach. The in-
dexed EOA was calculated by indexing the EOA to the
patient’s body surface area, computed using Dubois’ for-
mula. According to the literature, patient–prosthesis mis-
match was defined as an indexed EOA 1.2 cm2/m2 (23).
Clinical follow-up was performed at 30 days and 6 months,
if applicable.
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343Data management and statistical methods. Baseline, pro-
cedural, and follow-up data were prospectively entered
into a database and retrospectively analyzed. Continuous
variables are expressed as mean  SD if normally
distributed or median plus interquartile range (IQR) if
skewed or ordinal. Categorical variables are expressed as
frequencies and proportions (%). The differences in mean
values of continuous variables before and after the inter-
vention were compared using the paired Student t test or
the Wilcoxon matched-pairs signed rank test for ordinal
values, generating 2-tailed p values. Statistical signifi-
cance was assumed at p  0.05. All statistical analyses
ere performed using GraphPad Prism version 5.02
GraphPad Software Inc., La Jolla, California).
Ethics. All patients were fully informed about the valve-in-
valve procedure and signed written consent forms.
Results
Baseline characteristics. The study population was 100%
female with a mean age of 74.7  14.6 years (range: 52 to
88 years). All patients were highly symptomatic with a
median New York Heart Association (NYHA) functional
class of 3.0 (IQR: 3.0 to 3.5). Patients were admitted with
severe dysfunction of the implanted bioprostheses 10.5 
4.1 years after surgical MVR. Five patients had stented
bioprostheses size 27 mm in situ, whereas 1 patient had
received a 31-mm valve. Overall, 5 patients primarily
Table 1. Baseline Clinical Parameters
Patient #
Age
(yrs) Log ES STS-PROM
NYHA
Functional Class Comorbid
1 88 48.2% 26.8% 3 AF, previous stroke, gastr
bleeding, and breast c
2 83 22.3% NA* 4 Previous AVR with dysfun
persistent anemia due
gastrointestinal bleedi
dysplasia, pacemaker i
3 86 40.3% NA* 3 Decompensated HF, aorti
previous stroke, cereb
CAD, CABG, and PCI
4 62 48.7% 29.4% 3 Decompensated HF, prev
TVR for endocarditis w
encephalopathy, intrac
chronic hemodialysis f
previous stroke, previo
bleeding, CAD
5 52 11.1% 9.7% 3 Severe destructive rheum
circular calciﬁcation of
annulus, IDDM
6 75 26.6% 9.2% 3 Hemolytic anemia, von W
CAD, previous breast c
*STS-PROM not available for combined aortic and mitral valve procedures.
AF atrial fibrillation; AVR aortic valve replacement; CABG coronary artery bypass grafting
dependent diabetes mellitus; log ES  logistic European system for cardiac operative risk evaluat
pulmonary artery pressure; PCI percutaneous coronary intervention; STS PROM Society of Tho
regurgitation; TVR tricuspid valve replacement.displayed signs of regurgitation of the previously im- eplanted xenograft due to different etiologies, whereas 1
patient presented with prevailing stenosis and concomi-
tant regurgitation. Risk score predicted a 30-day mortal-
ity of 33  15% (logistic EuroSCORE) and 19  11%
(Society of Thoracic Surgeons predicted risk of mortal-
ity). Hemolytic anemia, most likely due to severe mitral
regurgitation (MR), was seen in 1 patient.
Concomitant aortic valve disease was present in 2 pa-
tients. In 1, the 23-mm Carpentier-Edwards porcine valve
in the aortic position featured calcified leaflets accounting
for a moderate stenosis (EOA: 1.1 cm2, mean transpros-
thetic gradient: 18 mm Hg, Patient #2). In the other, severe
calcific stenosis of the native aortic valve was identified
(EOA: 0.9 cm2, Patient #3).
Due to their severe comorbidities, 2 younger patients
were also considered suitable for transcatheter valve-in-
valve implantation: One patient suffered from severe
destructive rheumatoid arthritis with continuous immu-
nosuppression and pronounced circular calcification of
the mitral annulus (Patient #5). Multiple valve surgeries
due to endocarditis had been performed on another
patient who had suffered from septic encephalopathy and
chronic renal failure (Patient #4). Detailed patient data and
comorbidities are listed in Table 1; mitral valve characteristics
are listed in Table 2.
Procedural outcomes. Transcatheter mitral valve-in-valve
mplantation was performed successfully without the use of
Previous
Sternotomies
Creatinine
(mg/dl)
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(mm Hg)
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inal 1: MVR 1.6 44 2 50%
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urrent
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coronary artery disease; EF left ventricular ejection fraction; HF heart failure; IDDM insulin
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344stent diameters were measured as 23.0  1.3 mm. Subse-
quently, 23- and 26-mm Edwards Sapien valves were used
in 3 patients each. Two of the 6 patients received additional
procedures: One patient underwent concomitant transcath-
eter aortic valve implantation (TAVI) through the same
transapical access for a calcific aortic valve stenosis. A
second patient received a transcatheter valve-in-valve
implantation into a dysfunctional bioprosthesis in the
aortic position (Fig. 3). Including these additional pro-
cedures, operating time was 100.2  20.4 min. Median
fluoroscopy time was 428 (IQR: 264 to 977) s with 20.0
(IQR: 9.5 to 218.0) ml of contrast agent used. In patients
with isolated mitral valve-in-valve implantation, 0 to 20
ml of contrast dye were infused.
Valve function. In the mitral position, mean transvalvular
radients improved from 11.3  5.2 mm Hg to 5.5  3.6
m Hg (p 0.016) after implantation, and the EOA remained
nchanged (2.4 0.6 cm2 vs. 2.3 0.2 cm2). When adjusted
o body surface areas, indexed EOAs were 1.4  0.1
Figure 1. Ex Vivo Crimping and Mitral Valve-in-Valve Implantation
For transapical mitral valve-in-valve implantation, the 26-mm Sapien XT va
in a reverse fashion when compared with transapical aortic valve implanta
porcine (Edwards Lifesciences) mitral prosthesis and deployed to slightly over
roscopy demonstrates circular stent expansion and adequate approximatio
implantation (F to H).m2/m2 after implantation. Patient–prosthesis mismatch, as aefined by an indexed EOA 1.2 cm2/m2, did not occur in
ny patients after transcatheter valve-in-valve implantation.
edian MR was reduced from grade 3.0 (2.7 to 3.1) to 0
IQR: 0 to 1.0, p  0.033), with only 2 patients experienc-
ng trace MR after implantation.
In the aortic position, concomitant TAVI extended the
OA from 0.9 to 1.5 cm2 (Patient #3). Additional valve-
n-valve implantation only marginally improved the EOA
rom 1.1 to 1.2 cm2 with a reduction in mean transvalvular
gradients from 18 to 8 mm Hg (Patient #2).
Clinical outcomes. Two patients suffered from apical bleed-
ng late in the periprocedural course: One patient required
urgical rethoracotomy on postoperative day 4 due to
emothorax and experienced an uneventful recovery there-
fter (Patient #2). After a primarily uneventful course, a
econd patient suffered from acute hemodynamic compro-
ise on day 6 requiring cardiopulmonary resuscitation
Patient #1). The patient subsequently died, and autopsy
dentified hemorrhagic shock due to acute bleeding from the
wards Lifesciences, Irvine, California) is crimped onto the delivery system
and B). The THV is positioned within the 27-mm Carpentier Edwards
sewing ring toward the left atrium for sufﬁcient anchoring (C and D). Fluo-
Final results conﬁrm appropriate geometry after mitral valve-in-valvelve (Ed
tion (A
lap the
n (E).pical wound as the cause of death.
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345Overall length of stay in-hospital was 9.6  3.6 days
with 1.5  0.5 days in the intensive care unit. Although
3 of the 6 patients presented with concomitant renal
dysfunction, no signs of acute kidney injury became
obvious in the 5 patients discharged from our hospital.
Overall, serum creatinine was 1.2  0.5 mg/dl at baseline
and 1.3  0.8 mg/dl at discharge. Amount of packed red
blood cells transfused in the early course after the
procedure was 3.6  1.7 U per patient. There were no
adverse neurological events or arrhythmias necessitating
pacemaker implantation in any of these patients. No
clinical signs of hemolytic anemia were present in any of
the patients following the procedure.
Clinical follow-up. At a median follow-up of 70 (IQR: 25.5
o 358) days, 5 patients were alive without the occurrence of
ny valve-related adverse events. Heart failure improved
rom median NYHA functional class 3.0 (IQR: 3.0 to 3.5)
o 2.0 (IQR: 1.5 to 2.0, p  0.048) at the last visit, and all
atients were in good clinical condition. Echocardiographic
ollow-up demonstrated proper mitral valve-in-valve func-
ion. No signs of structural valve deterioration were noted at
his early stage.
One patient was readmitted with gastrointestinal bleed-
ng in the light of anticoagulation and sepsis 2 months after
he procedure. No signs of endocarditis were found, and the
atient could be discharged after resolution of symptoms
Figure 2. Step-by-Step Transapical Mitral Valve-in-Valve Implantation
After transapical insertion, the retrogradely crimped 26-mm Edwards Sapien X
lap the stent of the 31-mm Medtronic Mosaic valve (Medtronic, Minneapolis, M
left atrium ruling out signiﬁcant MR (E) after baseline echocardiography had d
markers in some bioprostheses, echocardiographic guidance becomes essentiander medical treatment.iscussion
Reoperative mitral valve replacement can be associated
with considerable mortality in elderly patients with co-
morbidities. Reported 30-day mortality rates ranged from
5.8% to 15.1% and 11.5% to 14.3% if combined with
reoperative aortic valve surgery (1–5). Recent guidelines
(21) recommend mitral valve surgery in patients with
chronic severe MR and symptoms in the absence of
severe left ventricular dysfunction (Class: I, Level of
Evidence: B). Because of the operative risk and promising
short- and mid-term results with TAVI (24,25), valve-
in-valve procedures have been applied in these high-risk
patients. However, due to the lack of durability data and the
excellent long-term results achieved with conventional valve
surgery, these novel approaches still demand special consid-
eration of patient selection criteria. Particularly elderly
patients with a significant-risk profile and indications for
complex reoperations may benefit from these techniques.
All patients described in this case series had an indication
for reoperative valve surgery according to recent guidelines
(21) but were considered high risk for conventional surgery
by an interdisciplinary heart team consisting of cardiologists
and cardiac surgeons. Severe comorbidities, such as destruc-
tive rheumatoid arthritis, bleeding disorders, and circular
calcification of the mitral annulus did not necessarily find
thesis (Edwards Lifesciences) is positioned (A) and deployed to slightly over-
ota) (B to D). Ventriculography without signs of contrast passage into the
ed severe eccentric MR before the procedure (F). Due to limited radiolucent
ent 6.T pros
innes
isplayreflection in the employed risk-stratification tools, empha-
m
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346sizing the need for thorough interdisciplinary patient eval-
uation. Thus, 2 younger patients also underwent transcatheter
itral valve-in-valve implantation since conventional surgery was
onsidered extremely high risk in these 2 patients.
As advocated by most other groups (11,12,14), we used
he transapical approach with successful implantation in all
atients. Transapical access is easy to set up and offers a
traight and short route to the mitral plane allowing for
Figure 3. Transcatheter Double Valve-in-Valve Implantation
Degenerated bioprostheses in the aortic and mitral positions (A) required imp
pentier-Edwards aortic and a 27-mm mitral prosthesis (Edwards Lifesciences) (
mitral valve-in-valve implantation; Patient #2.
Table 2. Mitral Valve Characteristics
Patient # Valve Type
Size
(mm)
ID
(mm) Failure Mode
Years
After
MVR
Meas
(
1 CE porcine 27 25 MR leaﬂet
prolapse
12
2 CE porcine 27 25 MR reduced
leaﬂet
mobility
16
3 CE porcine 27 25 MR leaﬂet
prolapse
12
4 Medtronic, Hancock II 27 24 MR leaﬂet
perforation
4
5 SJM biocor 27 25 MS 8
6 Medtronic Mosaic 31 28 MR leaﬂet
prolapse
11
The valves and their manufacturers are as follows: CE porcine (Carpentier-Edwards Porcine mitra
Hancock II mitral valve and Medtronic Mosaic mitral valve (Medtronic, Minneapolis, Minnesota); SJM
EOA effective orifice area; ID inner stent diameter according to manufacturers’ specification
measurements;MRmitral regurgitation;MSmitral stenosis;MVmitral valve;MVRmitral valVGmean transvalvular gradient.coaxial alignment of the transcatheter within the degener-
ated bioprosthesis (Fig. 4). Additionally, this approach
offered the opportunity to simultaneously access the aortic
valve in 2 of the 6 patients (Fig. 3). Nevertheless, we
experienced significant bleeding from the apical cannulation
site in the first 2 patients, 1 of whom expired in hemorrhagic
shock. Ventricular tissue may be very fragile in this select
patient cohort, and implantation in mitral position may be
ion of 23-mm Edwards Sapien valves (Edwards Lifescienes) into a 23-mm Car-
C). Echocardiography displaying valve function before (D) and after (E)
D
THV Type
Size
(mm)
Baseline
VG
(mm Hg)
Final VG
(mm Hg)
Baseline
EOA
(cm2)
Final
EOA
(cm2)
Baseline
MR
Grade
Final
MR
Grade
Sapien 23 9 3 2.5 2.3 3 TV 0-1
Sapien 23 15 4 3.3 2.3 3 0
Sapien XT 26 6 7 2.2 2.5 3 0
Sapien XT 26 10 5 2.4 2.4 3–4 PV 1
Sapien XT 23 20 12 1.7 2.0 2 0
Sapien XT 26 8 2 NA NA 3 0
Edwards Lifesciences, Irvine, California); Sapien and Sapien XT (Edwards Lifesciences); Medtronic
r (St. Jude Medical biocor mitral valve, St. Jude Medical, St. Paul, Minnesota).
sured ID inner stent diameter according to intraprocedural transesophageal echocardiographic
cement; NAnot available; PVperivalvular; THV transcatheter heart valve; TV transvalvular;lantat
B andured I
mm)
22
22
24
23
22
25
l valve,
bioco
s; mea
ve repla
(D) an
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347associated with more manipulation of the transapically
inserted sheath, emphasizing the need for careful applica-
tion of the purse-string sutures and meticulous control of
bleeding after sheath removal. This is also reflected in the
transfusion requirements of the reported case series. The
transseptal and transatrial routes seem technically more
demanding and may be reserved for patients not suitable for
the transapical approach.
Careful echocardiographic measurements of the inner
stent diameter are helpful for correct sizing of the THV
since the inner diameter of the degenerated bioprostheses
may deviate from the manufacturer’s specifications. Calci-
fied or torn tissue leaflets and pannus may impose altera-
tions on inner stent geometry as is being suggested by the
differences in the obtained baseline echocardiographic mea-
surements and manufacturer’s specifications in our experi-
ence (Table 2). Oversizing—as usually performed in native
valves—is impeded due to the rigid xenograft stent, and
valve underexpansion may contribute to increased gradients
and regurgitation through leaflet distortion and early valve
failure. Of particular note, the inner stent diameter differs
distinctly from the labeled valve size, which usually repre-
sents the outer stent diameter. A chart providing these
dimensions for a variety of mitral bioprostheses is included
in the Online Appendix.
The optimal imaging modality to evaluate the aortic or
mitral annulus geometry and THV size still remains to be
Figure 4. Transapical Access Allows for Coaxial Valve-in-Valve Alignment
Implantation of a 23-mm Edwards Sapien valve (Edwards Lifesciences) into a 2
lap over the surgical stent as illustrated by the radiolucent material (B) and cir
depicting leaﬂet prolapse with concomitant severe mitral regurgitation beforedetermined. Several studies have compared transesophagealand transthoracic echocardiography with multislice com-
puted tomography (26,27), with the latter technique taking
the elliptic shape of the aortic annulus into consideration,
therefore yielding larger annular measurements. The devel-
opment of second-generation THV aiming at anatomical
orientation may promote 3-dimensional reconstruction us-
ing multislice computed tomography or echocardiography.
At this point, information from multiple imaging modalities
and manufacturer’s specifications should be incorporated
into THV size choice.
The benefit of balloon valvuloplasty before valve-in-valve
implantation is unclear, but its downsides are well known.
Therefore, we used this technique only in 1 patient in whom
passage of the extensively calcified xenograft with the THV
was not feasible before valvuloplasty. No valvuloplasty was
performed in the remaining patients, and we did not
encounter any problems with regard to incomplete stent
expansion in these procedures. Similar to aortic valve-in-
valve procedures, implantation was performed with a slight
atrial overlap of the THV over the stent of the degenerated
bioprosthesis, allowing for sufficient anchoring and valve
expansion (Fig. 1) (11).
Valve function improved with a decrease of regurgitation,
mean transvalvular gradients, and unchanged EOA. A
mean transvalvular gradient of 5.5 mm Hg persisted, ac-
counting for a mild stenosis. This may have been due to
implantation into smaller bioprostheses labeled 27 mm in 5
Carpentier-Edwards prosthesis (Edwards Lifesciences) (A) with a slight over-
expansion within the failing xenograft (C). Echocardiographic evaluation
d adequate valve function after the procedure (E); Patient #1.7-mm
cularof 6 patients and is in agreement with previously published
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348data (11). Higher degrees of stenosis in small-size biopros-
theses and the subsequent problem of patient–prosthesis
mismatch did not occur in our experience, as opposed to
aortic valve-in-valve implantation (28). MR, the leading
pathology in 5 of 6 patients, was sufficiently reduced, with
only trace regurgitation remaining in 2 patients. Regarding
the 2 patients with double valve procedures, improvement in
valve function was only marginal after concomitant valve-
in-valve implantation in the aortic position. In both pa-
tients, mitral valve pathology qualified for the leading
indication. A later intervention in case of progressive aortic
valve disease may have been impeded by the previous mitral
valve-in-valve procedure. Therefore, both valves were
treated at the same time, even though stenosis was only
moderate in 1 patient. Additionally, transvalvular aortic
gradients may have been underestimated at baseline due to
mitral valve pathology.
Depending on the amount of radio-opaque markers
within the bioprostheses (Fig. 2 vs. Fig. 3), use of contrast
dye can be reduced or even omitted to conserve renal
function. In addition, transesophageal echocardiography
may be helpful in guiding implantation in patients with
largely radiolucent prostheses. Despite comparatively large
volumes of contrast agent used in combined procedures, no
acute kidney injury was observed in these patients. Length
of stay in the hospital of almost 10 days seems long in the
light of a transcatheter approach but may reflect the high-
risk patient population described in this case series. During
short-term follow-up, no valve-related adverse events or
structural deterioration was noted, and clinical improvement
with regard to symptoms and NYHA functional class was
seen immediately. However, no exercise testing was per-
formed to objectify these results. Furthermore, systematic
analyses of long-term data in a larger patient population
have to be performed to thoroughly evaluate this novel
approach.
Conclusions
Reoperative mitral valve replacements are associated with an
elevated operative risk, especially in elderly patients with
multiple comorbidities. Sparing these patients the burden of
a complex on-pump surgery requiring repeat sternotomy is
an important advantage of a catheter-based approach. This
series of 6 high-risk patients who successfully underwent
mitral valve-in-valve implantation supports the notion that
this procedure may serve as a complementary approach to
reoperative mitral valve replacement in high-risk patients.
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APPENDIX
For a listing of the mitral bioprostheses dimensions according to manufac-
turers’ specifications, please see the online version of this article.
